MYCN and neuroblastoma: Interestingly, fusion-negative RMS and non-MYCN-amplified NB are considered to have better prognosis compared with less favourable subgroups of patients; however, unresolved questions persist regarding the optimal management for these groups of patients given that some cases can still relapse and/or metastasize.